gene_symbol
FCGR2A
hgnc_id
HGNC:3616
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Tafasitamab binds CD19 on B cells; its Fc engages FcγRIIa (CD32A) on myeloid effector cells to drive ADCC/ADCP of CD19+ targets. CD32A-expressing cells are not targeted for killing and act as effectors.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated ADCP engagement
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05366218
disease_id_num_tar_ref
5084
drug_id_num_tar_ref
13740